Who
Jason Raleigh Nunn
Director
Company insider
Files Form 4 as: Director, Addex Therapeutics; Director, Zenas BioPharma; Director, Regulus Therapeutics; Director, Trevena; Director, Dermira; Director, TriVascular Technologies; Director, Hyperion Therapeutics; Director, Transcept Pharmaceuticals.
In numbers
- Trades disclosed
- 91
- Buys
- 2
- Sells
- 0
- Bought
- $16.2M
- Sold
- $0
- Companies
- 8
- Companies where not an officer
- 8
- First trade
- 14 Jan 2010
- Last trade
- 2 Sep 2026
- Last filed
- 4 Sep 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code D | —219,561 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code A | —219,561 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code D | —219,561 at $0.00 | filing |
| 2 Sep 2026filed 4 Sep 2026 | ADXN Addex TherapeuticsBiotechnology | SEC FORM 4 Code A | —219,561 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 15 Jun 2026filed 17 Jun 2026 | ZBIO Zenas BioPharmaoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,500 at $0.00 | filing |
| 9 Oct 2025filed 14 Oct 2025 | ZBIO Zenas BioPharmaBiotechnology | SEC FORM 4 Bought | $1.2M63,158 at $19.00 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,650 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —2,325 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —4,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —9,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —15,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —30,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeuticsoption or derivative | SEC FORM 4 Code D | —60,000 | filing |
| 25 Jun 2025filed 27 Jun 2025 | Regulus Therapeutics | SEC FORM 4 Code D | —62,500 | filing |
News
Head to Head Review: Kiniksa Pharmaceuticals International (NASDAQ:KNSA) versus Zenas BioPharma (NASDAQ:ZBIO)ZBIO · themarketsdaily.com · 18 Oct 2026Head-To-Head Contrast: Zenas BioPharma (NASDAQ:ZBIO) and MacroGenics (NASDAQ:MGNX)ZBIO · themarketsdaily.com · 14 Oct 2026Zenas BioPharma to Host Virtual R&D EventZBIO · manilatimes.net · 6 Oct 2026
0 headlines in the last 90 days name Jason Raleigh Nunn; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.